MX2020008180A - Anticuerpos activables y métodos para elaborarlos y usarlos. - Google Patents
Anticuerpos activables y métodos para elaborarlos y usarlos.Info
- Publication number
- MX2020008180A MX2020008180A MX2020008180A MX2020008180A MX2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A MX 2020008180 A MX2020008180 A MX 2020008180A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- activatable antibodies
- activatable
- binding polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/075065 WO2019148445A1 (en) | 2018-02-02 | 2018-02-02 | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| PCT/CN2019/074581 WO2019149282A1 (en) | 2018-02-02 | 2019-02-02 | Activatable antibodies and methods of making and using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008180A true MX2020008180A (es) | 2020-10-19 |
Family
ID=67476415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008180A MX2020008180A (es) | 2018-02-02 | 2019-02-02 | Anticuerpos activables y métodos para elaborarlos y usarlos. |
| MX2025005685A MX2025005685A (es) | 2018-02-02 | 2020-08-03 | Anticuerpos activables y metodos para elaborarlos y usarlos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025005685A MX2025005685A (es) | 2018-02-02 | 2020-08-03 | Anticuerpos activables y metodos para elaborarlos y usarlos |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20190241886A1 (https=) |
| EP (1) | EP3746461A4 (https=) |
| JP (3) | JP2021512122A (https=) |
| KR (2) | KR20250106739A (https=) |
| CN (2) | CN121046961A (https=) |
| AU (2) | AU2019214189B2 (https=) |
| BR (1) | BR112020015380A2 (https=) |
| CA (1) | CA3090027A1 (https=) |
| IL (2) | IL326606A (https=) |
| MX (2) | MX2020008180A (https=) |
| SG (1) | SG11202007166XA (https=) |
| WO (2) | WO2019148445A1 (https=) |
| ZA (1) | ZA202005260B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| BR112020021269A2 (pt) | 2018-04-18 | 2021-03-16 | Exelixis, Inc. | Construções de anticorpo anti-ror |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021148006A1 (en) * | 2020-01-23 | 2021-07-29 | Adagene Ag | Heterodimeric proteins with fc mutations |
| WO2021226883A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer submission of sequence listing on ascii text file |
| US20220119549A1 (en) * | 2020-10-15 | 2022-04-21 | Tavotek Biotherapeutics (Hong Kong) Limited | Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| JP2024517381A (ja) * | 2021-04-11 | 2024-04-22 | アダジーン インコーポレイテッド | がんを治療するための併用療法 |
| WO2023168547A1 (en) * | 2022-03-07 | 2023-09-14 | Adagene Pte. Ltd. | Anti-cd137 antibodies and methods of making and using the same |
| WO2023193239A1 (en) * | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| JP2026501281A (ja) | 2022-12-21 | 2026-01-14 | ジェンザイム・コーポレーション | 抗ｐｄ－１×４－１ｂｂ結合タンパク質 |
| AR131856A1 (es) | 2023-02-16 | 2025-05-07 | Sanofi Sa | Proteínas de unión a cd40 |
| WO2024212152A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2024212151A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Masked antibodies, libraries and methods of use |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| WO2025066568A1 (zh) * | 2023-09-25 | 2025-04-03 | 深圳湾实验室 | 可激活穿膜构建体和降解子 |
| CN121517565A (zh) * | 2023-09-25 | 2026-02-13 | 深圳湾实验室 | 可激活穿膜构建体和降解子 |
| AR134514A1 (es) | 2023-12-01 | 2026-01-21 | Gilead Sciences Inc | Proteína de fusión anti-fap-ligera y uso de esta |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DE69233408T2 (de) | 1991-12-02 | 2005-09-22 | Cambridge Antibody Technology Ltd., Melbourn | Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US7138500B1 (en) | 1993-05-07 | 2006-11-21 | Immunex Corporation | Antibodies to human 4-1BB |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| ES2185770T3 (es) | 1995-04-08 | 2003-05-01 | Lg Chemical Ltd | Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| JP4200627B2 (ja) | 2000-03-01 | 2008-12-24 | 味の素株式会社 | 変異型チロシンリプレッサー遺伝子とその利用 |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| WO2002055106A2 (en) | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| CA2477947A1 (en) | 2002-03-01 | 2003-09-12 | Dyax Corp. | Modular recombinatorial display libraries |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| AR046094A1 (es) | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20070253961A1 (en) | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| US20080152655A1 (en) | 2004-09-08 | 2008-06-26 | The Ohio State University Research Foundation | Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies |
| US20060153808A1 (en) | 2004-11-17 | 2006-07-13 | Board Of Regents, The Universtiy Of Texas System | Cancer immunotherapy incorporating p53 |
| DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| WO2006088447A1 (en) | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA2610661A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| CA2619298C (en) | 2005-08-26 | 2017-07-04 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| CN1294146C (zh) | 2005-10-17 | 2007-01-10 | 山东大学 | 与t细胞表面共刺激分子cd137结合的多肽及其应用 |
| WO2007062093A2 (en) | 2005-11-22 | 2007-05-31 | Incyte Corporation | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| NZ583019A (en) | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| EP2190440A1 (en) | 2007-08-13 | 2010-06-02 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| AU2013202755B2 (en) | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| ES2336873B1 (es) | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| WO2010132389A2 (en) | 2009-05-14 | 2010-11-18 | University Of Maryland, Baltimore | Methods for treating cancers and diseases associated with 4-1bb (cd137) expression |
| US9193791B2 (en) * | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| MX2014016038A (es) | 2012-06-22 | 2015-08-14 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos. |
| WO2014139130A1 (en) | 2013-03-14 | 2014-09-18 | Adagene Inc. | An integrated system for library construction, affinity binder screening and expression thereof |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CA2925106C (en) * | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| MX2016007885A (es) | 2013-12-17 | 2017-01-11 | Genentech Inc | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. |
| EP3082839A4 (en) | 2013-12-20 | 2017-08-09 | National University of Singapore | Differentiation therapy with cd137 ligand agonists |
| MX385194B (es) | 2014-02-21 | 2025-03-14 | Nektar Therapeutics India Pvt Ltd | Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| CN108271359B (zh) | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2984892A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| CN107849133B (zh) | 2015-05-04 | 2022-08-23 | 西托姆克斯治疗公司 | 抗cd166抗体、可活化抗cd166抗体及其使用方法 |
| JP2018520650A (ja) | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | 新規のポリペプチド |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| CN114591433A (zh) * | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| HRP20201022T1 (hr) | 2015-09-22 | 2020-10-16 | Dingfu Biotarget Co., Ltd | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| FI3389699T3 (fi) | 2015-12-15 | 2024-05-28 | Oncoc4 Inc | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| EP3394107A1 (en) | 2015-12-22 | 2018-10-31 | AbbVie Stemcentrx LLC | Novel anti-tnfsf9 antibodies and methods of use |
| EP3417293A1 (en) | 2016-02-18 | 2018-12-26 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
| AU2017225787B2 (en) | 2016-03-03 | 2021-09-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| EP3464362B1 (en) | 2016-05-27 | 2020-12-09 | AbbVie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
| SG11201811431VA (en) | 2016-07-14 | 2019-01-30 | Genmab As | Multispecific antibodies against cd40 and cd137 |
| CN107840887B (zh) | 2016-09-21 | 2022-03-25 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| US10174122B2 (en) | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| KR20180119135A (ko) | 2017-04-24 | 2018-11-01 | 주식회사 제넥신 | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 |
| RU2019138067A (ru) | 2017-05-02 | 2021-06-02 | Эллигейтор Биосайенс Аб | Биспецифическое антитело против ox40 и ctla-4 |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| SG11201913137VA (en) | 2017-07-11 | 2020-01-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| EP3673100A4 (en) | 2017-08-21 | 2021-04-21 | Adagene Inc. | DYNAMIC LIBRARIES FOR HUMAN ANTIBODIES WITH A LIGHT CHAIN |
| SG11202001551YA (en) | 2017-08-21 | 2020-03-30 | Adagene Inc | Dynamic human heavy chain antibody libraries |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| WO2019104716A1 (en) | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| AU2020287181A1 (en) | 2019-06-05 | 2022-01-20 | Adagene Pte. Ltd. | Anti-CD137L antibodies and methods of using same |
| TW202200622A (zh) | 2020-05-13 | 2022-01-01 | 瑞士商天演藥業公司 | 用於治療癌症之組成物及方法 |
| CN116600805A (zh) | 2020-06-23 | 2023-08-15 | 天演药业公司 | 包含抗cd137抗体的组合疗法 |
| WO2023168547A1 (en) * | 2022-03-07 | 2023-09-14 | Adagene Pte. Ltd. | Anti-cd137 antibodies and methods of making and using the same |
-
2018
- 2018-02-02 WO PCT/CN2018/075065 patent/WO2019148445A1/en not_active Ceased
-
2019
- 2019-02-01 US US16/265,851 patent/US20190241886A1/en not_active Abandoned
- 2019-02-02 CN CN202511032704.1A patent/CN121046961A/zh active Pending
- 2019-02-02 CN CN201980021653.9A patent/CN112771066B/zh active Active
- 2019-02-02 IL IL326606A patent/IL326606A/en unknown
- 2019-02-02 KR KR1020257021619A patent/KR20250106739A/ko active Pending
- 2019-02-02 JP JP2020541957A patent/JP2021512122A/ja active Pending
- 2019-02-02 EP EP19747798.7A patent/EP3746461A4/en active Pending
- 2019-02-02 MX MX2020008180A patent/MX2020008180A/es unknown
- 2019-02-02 BR BR112020015380-0A patent/BR112020015380A2/pt unknown
- 2019-02-02 SG SG11202007166XA patent/SG11202007166XA/en unknown
- 2019-02-02 US US16/966,848 patent/US11952681B2/en active Active
- 2019-02-02 KR KR1020207024940A patent/KR102828375B1/ko active Active
- 2019-02-02 WO PCT/CN2019/074581 patent/WO2019149282A1/en not_active Ceased
- 2019-02-02 CA CA3090027A patent/CA3090027A1/en active Pending
- 2019-02-02 AU AU2019214189A patent/AU2019214189B2/en active Active
-
2020
- 2020-07-26 IL IL276285A patent/IL276285B1/en unknown
- 2020-08-03 MX MX2025005685A patent/MX2025005685A/es unknown
- 2020-08-24 ZA ZA2020/05260A patent/ZA202005260B/en unknown
-
2023
- 2023-01-11 US US18/153,221 patent/US20240150749A1/en active Pending
- 2023-06-19 JP JP2023099859A patent/JP7596450B2/ja active Active
-
2024
- 2024-09-11 AU AU2024219607A patent/AU2024219607A1/en active Pending
- 2024-11-27 JP JP2024206403A patent/JP2025037964A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240150749A1 (en) | 2024-05-09 |
| CN121046961A (zh) | 2025-12-02 |
| AU2019214189A1 (en) | 2020-09-17 |
| US20190241886A1 (en) | 2019-08-08 |
| JP2023134458A (ja) | 2023-09-27 |
| EP3746461A4 (en) | 2021-11-17 |
| CN112771066B (zh) | 2025-08-08 |
| AU2024219607A1 (en) | 2024-10-03 |
| US11952681B2 (en) | 2024-04-09 |
| CA3090027A1 (en) | 2019-08-08 |
| MX2025005685A (es) | 2025-06-02 |
| BR112020015380A2 (pt) | 2020-12-22 |
| JP2021512122A (ja) | 2021-05-13 |
| IL276285B1 (en) | 2026-03-01 |
| SG11202007166XA (en) | 2020-08-28 |
| AU2019214189B2 (en) | 2024-06-27 |
| CN112771066A (zh) | 2021-05-07 |
| ZA202005260B (en) | 2024-12-18 |
| EP3746461A1 (en) | 2020-12-09 |
| KR20200128011A (ko) | 2020-11-11 |
| IL326606A (en) | 2026-04-01 |
| KR20250106739A (ko) | 2025-07-10 |
| WO2019149282A1 (en) | 2019-08-08 |
| WO2019148445A1 (en) | 2019-08-08 |
| JP2025037964A (ja) | 2025-03-18 |
| IL276285A (en) | 2020-09-30 |
| JP7596450B2 (ja) | 2024-12-09 |
| KR102828375B1 (ko) | 2025-07-03 |
| US20210207126A1 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202005260B (en) | Activatable antibodies and methods of making and using thereof | |
| NZ783169A (en) | Flt3l-fc fusion proteins and methods of use | |
| PH12022550195A1 (en) | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| WO2020142659A3 (en) | Multi-specific protein molecules and uses thereof | |
| PH12020550408A1 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
| PH12020551997A1 (en) | Psma binding agents and uses thereof | |
| EP4273233A3 (en) | Mr1 restricted t cell receptors for cancer immunotherapy | |
| CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
| MX2024003807A (es) | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos. | |
| EP4442706A3 (en) | Canine antibody libraries | |
| ZA202309861B (en) | Proteins comprising cd3 antigen binding domains and uses thereof | |
| TN2018000325A1 (en) | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123. | |
| MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
| PH12022500023A1 (en) | Proteins comprising cd3 antigen binding domains and uses thereof | |
| MX2023001256A (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos. | |
| PH12022551462A1 (en) | Ilt3-binding agents and methods of use thereof | |
| GB2596001A8 (en) | Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner | |
| MX2022009674A (es) | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. | |
| PH12022552370A1 (en) | Materials and methods for binding siglec-3/cd33 | |
| MX2024002753A (es) | Anticuerpos anti receptor de transferrina y usos de los mismos. | |
| MX2023009615A (es) | Moleculas de union anti-cd123 y usos de estas. | |
| EP4417686A3 (en) | Polypeptides, nucleic acid molecules, cells, and related methods | |
| MX2022001219A (es) | Dominios variables humanos modificados. |